Differentially Expressed MicroRNAs in Meningiomas Grades I and II Suggest Shared Biomarkers with Malignant Tumors

Abstract

Meningiomas represent the most common primary tumors of the central nervous system, but few microRNA (miRNA) profiling studies have been reported so far. Deep sequencing of small RNA libraries generated from two human meningioma biopsies WHO grades I (benign) and II (atypical) were compared to excess dura controls. Nineteen differentially expressed miRNAs were validated by RT-qPCR using tumor RNA from 15 patients and 5 meninges controls. Tumor suppressor miR-218 and miR-34a were upregulated relative to normal controls, however, miR-143, miR-193b, miR-451 and oncogenic miR-21 were all downregulated. From 10 selected putative mRNA targets tested by RT-qPCR only four were differentially expressed relative to normal controls. PTEN and E-cadherin (CDH1) were upregulated, but RUNX1T1 was downregulated. Proliferation biomarker p63 was upregulated with nuclear localization, but not detected in most normal arachnoid tissues. Immunoreactivity of E-cadherin was detected in the outermost layer of normal arachnoids, but was expressed throughout the tumors. Nuclear Cyclin D1 expression was positive in all studied meningiomas, while its expression in arachnoid was limited to a few trabecular cells. Meningiomas of grades I and II appear to share biomarkers with malignant tumors, but with some additional tumor suppressor biomarkers expression. Validation in more patients is of importance.

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningiomain vitro

“…We next assessed the expression levels of cyclin D1 and p27kip1, which are two proteins involved in the cell cycle, that are modulated by SSAs in neuroendocrine tumors [ 18 ] and expressed in meningiomas [ 21 , 22 ] by western blotting in eight meningioma samples (six WHO grade I and two WHO grade II). Alone or in combination with everolimus, pasireotide decreased cyclin D1 expression to a higher degree than octreotide ( p < 0.05, Figure 3C , 3D ).…”

MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN

“…MiRNA profiling studies have shown that the expression level of miR-193b is frequently downregulated in human cancer tissues as compared to non-cancerous adjacent tissues. Reduced expression levels of miR-193b as compared to (adjacent) non-cancerous cells were found in ovarian [ 49 ], hepatocellular carcinoma [ 34 , 42 ], non-small cell lung cancer (NSCLC) cells [ 37 ], meningioma [ 50 ] and endometrioid adenocarcinoma [ 51 ], and also in pancreatic [ 52 ] and gastric [ 53 , 54 ] cancer cells. In other cancer types, including glioma [ 55 ], multiple myeloma [ 56 ] and head and neck squamous cell carcinoma (HNSCC) [ 57 ], the expression of miR-193b has been reported to be upregulated compared to non-cancerous cells, and increased miR-193b expression levels were found in relapsed relative to non-relapsed primary HNSCC tissues [ 57 ].…”

microRNAs and Markers of Neutrophil Activation as Predictors of Early Incidental Post-Surgical Pulmonary Embolism in Patients with Intracranial Tumors

“…microRNAs (miRNAs) are small non-coding RNAs that regulate protein expression, and have been suggested as regulatory molecules and biomarkers in practically all cancer types [11]. In the particular scenario of intracranial tumors, several miRNAs have been proposed as biomarkers in glioma [12][13][14][15][16] and meningioma [17][18][19], and even these molecules have been proposed to have therapeutic benefits in these tumors [20,21]. However, to date, the role of miRNAs in the stratification of VTE risk in patients with intracranial tumors has never been explored.…”